Pilot Study for a New Quasiorganelle Therapy in Dogs with Histiocytic Sarcoma

New university findings highlight potential implications for dogs, oncology, and veterinary practice.

Pilot Study for a New Quasiorganelle Therapy in Dogs with Histiocytic Sarcoma | College of Veterinary Medicine at MSU Support the College of Veterinary Medicine Search Tool Clinical Trials Select Chronic Kidney Disease in Cats Direct Comparison of CHOP and LOPP Chemotherapy and Genomic Analysis for Naïve T Cell Lymphoma in Client-owned Dogs FAQs with Dr.

While some dogs experience benefits, these treatments affect many cells at once and cannot adapt as a tumor changes.

New research shows that cancer closely interacts with the immune system and surrounding tissues, suggesting that better treatments may need to work inside cells, not just target them from the outside.

Quasiorganelle therapy is an experimental approach that aims to do this by using weakened, non-disease-causing bacteria derived from Listeria monocytogenes to deliver helpful genetic instructions directly into immune and tumor cells, with the goal of improving how the body recognizes and responds to cancer.

The aim of this study is to determine whether quasiorganelle therapy can be given safely to dogs with histiocytic sarcoma and to determine an appropriate dosing schedule.

The treatment has been tested in laboratory and preclinical studies but not yet in dogs with naturally-occurring cancer.

Because animals with cancer may respond differently than healthy animals, this study also looks for early biological or clinical signs that the therapy may be beneficial.

Inclusion criteria: Confirmed diagnosis of histiocytic sarcoma, including hemophagocytic histiocytic sarcoma, as determined by immune marker expression.

Visible tumor at the time of enrollment.

Up to 5 lesions Sum of the longest lesion dimensions <15cm Adequate organ function indicated by standard laboratory tests.

Minimum weight requirement of 20 kg (44 lbs).

The report adds to ongoing university-led research relevant to veterinary medicine, animal health, and clinical decision-making.

Source university website: Michigan State University College of Veterinary Medicine

https://cvm.msu.edu/hospital/veterinarians/clinical-trials/pilot-study-for-a-new-quasiorganelle-therapy-in-dogs-with-histiocytic-sarcoma

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies